Skip to content
The Intraday Markets
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

OKUR Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

OKUR
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

OKUR Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

OKUR

$3.99
+$0.09 (2.31%)+2.31%
After Hours
Loading chart...
IndexN/A
Market Cap0.16B
Enterprise Value-0.02B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-1.14
P/S0.00
P/B0.70
P/C-0.76
EV/EBITDA0.33
EV/SalesN/A
EPS (ttm)-3.50
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume0.22M
Shs Outstand0.04B
Change2.31%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of Revenue$0.00$0.00$0.00$50.00K$37.00K
Gross Profit$0.00$0.00$0.00$-50.00K$-37.00K
Gross MarginN/AN/AN/AN/AN/A
Operating Expenses$54.39M$36.93M$29.77M$39.77M$19.52M
Operating Income$-54.39M$-36.93M$-29.77M$-39.82M$-19.55M
Operating MarginN/AN/AN/AN/AN/A
Net Income$-52.67M$-35.31M$-29.51M$-39.77M$-19.46M
Net MarginN/AN/AN/AN/AN/A
EPS (Basic)$-3.95$-2.65$-2.21$-21.92$-7.74
EBITDAN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/A
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020
Cash & Short Term InvestmentsN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/A
Total Assets$114.91M$35.73M$16.00M$154.02M$55.22M
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/A
Total Liabilities$11.08M$137.58M$70.42M$6.81M$97.34M
Non-Equity ReservesN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/A
Total Shareholders Equity$103.83M$-101.84M$-54.42M$147.21M$-42.12M
Accumulated Minority InterestN/AN/AN/AN/AN/A
Total Equity$103.83M$-101.84M$-54.42M$147.21M$-42.12M
Total Liabilities & Stockholders Equity$114.91M$35.73M$16.00M$154.02M$55.22M
Book Value Per ShareN/AN/AN/AN/AN/A
Tangible Book Value Per ShareN/AN/AN/AN/AN/A
Full-Time EmployeesN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/A
Return on AssetsN/AN/AN/AN/AN/A
Return on EquityN/AN/AN/AN/AN/A
Return on Invested CapitalN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/A
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020
Net Income$-52.67M$-35.31M$-29.51M$-39.77M$-19.46M
DepreciationN/AN/AN/AN/AN/A
Other Funds (Non Cash)N/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/A
Cash from Operating Activities$-51.12M$-34.55M$-26.95M$-37.98M$-18.54M
Capital ExpendituresN/AN/AN/AN/AN/A
Net Assets From AcquisitionsN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/A
Cash Dividends PaidN/AN/AN/AN/AN/A
Change in Capital StockN/AN/AN/AN/AN/A
Repurchase of Common Pref StockN/AN/AN/AN/AN/A
Sale of Common Pref StockN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/A
Free Cash FlowN/AN/AN/AN/AN/A
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/A

Company coverage

Latest news

2 stories
Jul 2 · 12:00PMOnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026GlobeNewswire Inc. ↗Dec 10 · 12:00PMOnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219GlobeNewswire Inc. ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
Agresta Samuel
Award
131.4K
$4.14
$544K
Aug 7, 26
Hartley Dylan
Award
137.6K
$4.14
$570K
Aug 7, 26
Leverone Jason A.
Award
130.6K
$4.14
$541K
Aug 7, 26
Saccomano Nicholas A
Award
542.2K
$4.14
$2.2M
Aug 7, 26
Carruthers R Michael
Award
22.4K
$4.14
$93K
Aug 7, 26

Company

CEO: Nicholas A. SaccomanoEmployees: 45onkuretherapeutics.com
About the company↓

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.

Discover more

You may be interested in
NVDA

NVIDIA Corp

$225.16

↓ 0.12%
MSFT

Microsoft Corp

$495.40

↓ 0.32%
JPM

JPMorgan Chase & Co

$362.84

↓ 0.20%
AMZN

Amazon.com Inc

$262.65

↓ 0.92%
PYPL

PayPal Holdings Inc

$61.66

↑ 1.68%
DIS

Walt Disney Co

$106.85

↑ 1.85%
ABX

Abacus Global Management Inc

$9.27

↑ 8.80%
TSLA

Tesla Inc

$342.27

↑ 0.53%
ADBE

Adobe Inc

$264.02

↓ 2.40%
IBM

IBM Corp

$234.32

↓ 1.16%
V

Visa Inc

$364.15

↓ 0.64%
MA

Mastercard Inc

$569.29

↑ 0.40%
The Intraday Markets

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC